Obesity pipeline
What is next, and who is running it?
The next dated milestone on each program. A hollow marker is a registry primary completion date, not a company readout.
ClassNone selected
MechanismNone selected
Phase 1 included.
Clear filters94 of 94 programs on this timeline
202520262027202820292030Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Today
GLP-1 RA 17
SemaglutideApproved
Registry, Sep 6, 2028
BeinaglutideStage n/r
No dated milestone in 2025 to 2030
BofanglutidePhase 3
Registry, Jun 30, 2027
DapiglutidePhase 2
No dated milestone in 2025 to 2030
DulaglutidePhase 3
No dated milestone in 2025 to 2030
EcnoglutidePhase 3
Registry, Jan 5, 2027
Efsubaglutide AlfaPhase 2/3
Registry, Nov 30, 2026
ExenatidePhase 3
No dated milestone in 2025 to 2030
HDM1002Phase 3
No dated milestone in 2025 to 2030
LiraglutideApproved
No dated milestone in 2025 to 2030
LixisenatidePhase 3
No dated milestone in 2025 to 2030
MazdutidePhase 3
Registry, Dec 31, 2026
Oral SemaglutidePhase 3
Registry, Feb 22, 2028
TaspoglutidePhase 3
No dated milestone in 2025 to 2030
TG103Phase 3
No dated milestone in 2025 to 2030
SupaglutidePhase 2/3
No dated milestone in 2025 to 2030
LotiglipronPhase 2
No dated milestone in 2025 to 2030
GLP-1/GIP 7
TirzepatideApproved
Registry, Jan 2027
VK2735Phase 3
Registry, Jul 2027
Oral VK2735Phase 3
No dated milestone in 2025 to 2030
BGM0504Phase 3
Registry, Feb 28, 2027
CT-388Phase 3
Registry, Nov 12, 2027
HDM1005Phase 3
Registry, Dec 2026
RibupatidePhase 3
Registry, Oct 31, 2027
GLP-1/glucagon 4
SurvodutidePhase 3
Registry, Dec 8, 2026
CotadutidePhase 1
No dated milestone in 2025 to 2030
EfinopegdutidePhase 1
No dated milestone in 2025 to 2030
PemvidutidePhase 2
No dated milestone in 2025 to 2030
GIP/GLP-1/glucagon 2
RetatrutidePhase 3
Registry, Mar 14, 2027
UBT251Phase 3
Registry, Jan 14, 2027
Amylin combo 1
Registry, Mar 2027
Oral small molecule 7
OrforglipronApproved
Registry, Sep 6, 2027
AleniglipronPhase 3
No dated milestone in 2025 to 2030
DanuglipronPhase 1
No dated milestone in 2025 to 2030
ElecoglipronPhase 3
Registry, Nov 18, 2026
SafiglipronPhase 3
No dated milestone in 2025 to 2030
TERN-601Phase 2
No dated milestone in 2025 to 2030
VCT220Phase 3
No dated milestone in 2025 to 2030
GLP-1 conjugate 1
Maridebart CafraglutidePhase 3
Registry, Jan 21, 2027
Amylin 6
EloralintidePhase 3
Registry, Mar 2028
PetrelintidePhase 3
Registry, Oct 20, 2028
ACCG-2671Phase 1/2
No dated milestone in 2025 to 2030
CagrilintidePhase 3
Registry, Jan 26, 2027
PramlintidePhase 2/3
No dated milestone in 2025 to 2030
ABBV-295Phase 2
No dated milestone in 2025 to 2030
Myostatin/activin 3
ApitegromabPhase 2
No dated milestone in 2025 to 2030
BimagrumabPhase 2
Registry, Dec 31, 2028
GaretosmabPhase 2
No dated milestone in 2025 to 2030
MC4R 1
SetmelanotidePhase 3
Registry, Mar 13, 2027
CB1 2
RimonabantPhase 3
No dated milestone in 2025 to 2030
MonlunabantPhase 2
No dated milestone in 2025 to 2030
Lipase inhibitor 1
OrlistatApproved
No dated milestone in 2025 to 2030
Opioid and antidepressant 1
Naltrexone And BupropionPhase 3
Registry, Dec 31, 2030
Sympathomimetic combo 1
Phentermine And TopiramatePhase 3
No dated milestone in 2025 to 2030
Monoamine reuptake 2
SibutraminePhase 3
No dated milestone in 2025 to 2030
TesofensinePhase 2
No dated milestone in 2025 to 2030
SARM 1
EnobosarmPhase 2
No dated milestone in 2025 to 2030
Class not reported 34
ZenagamtidePhase 3
Registry, Jun 12, 2028
NimacimabPhase 2
Registry, Nov 20, 2026
ARO-ALK7Phase 1/2
Registry, Feb 2027
SCO-940/CT-G32Preclinical
No dated milestone in 2025 to 2030
Eloralintide And TirzepatidePhase 3
No dated milestone in 2025 to 2030
ASC30Phase 3
No dated milestone in 2025 to 2030
BerobenatidePhase 3
Registry, Sep 21, 2027
CT-996Phase 1
No dated milestone in 2025 to 2030
HDM1702Phase 3
No dated milestone in 2025 to 2030
LoxenatidePhase 2/3
No dated milestone in 2025 to 2030
LY4086940Phase 2
No dated milestone in 2025 to 2030
VisepegenatidePhase 1/2
No dated milestone in 2025 to 2030
VRB-101Phase 2
No dated milestone in 2025 to 2030
BrenipatidePhase 1
No dated milestone in 2025 to 2030
CT-868Phase 2
No dated milestone in 2025 to 2030
DA-1726Phase 1
Registry, Nov 9, 2026
HM15211Phase 1
No dated milestone in 2025 to 2030
HS-20094Phase 3
Registry, Nov 13, 2026
MET-233IPhase 1/2
No dated milestone in 2025 to 2030
NNC0519-0130Phase 2
No dated milestone in 2025 to 2030
RAY1225Phase 3
No dated milestone in 2025 to 2030
PF-07976016Phase 2
No dated milestone in 2025 to 2030
AlbiglutidePhase 3
No dated milestone in 2025 to 2030
EfpeglenatidePhase 3
No dated milestone in 2025 to 2030
NoiiglutidePhase 3
No dated milestone in 2025 to 2030
CetilistatPhase 1
No dated milestone in 2025 to 2030
CRB-913Phase 1
No dated milestone in 2025 to 2030
GUB014295Phase 1
No dated milestone in 2025 to 2030
LB54640Phase 2
No dated milestone in 2025 to 2030
TaldefgrobepPhase 2
No dated milestone in 2025 to 2030
VelneperitPhase 2
No dated milestone in 2025 to 2030
NNC0165-1875Phase 2
No dated milestone in 2025 to 2030
AZD6234Phase 3
Registry, May 4, 2027
TrevogrumabPhase 2
No dated milestone in 2025 to 2030
MetAP2 inhibitor 1
BeloranibPhase 3
No dated milestone in 2025 to 2030
Serotonin agonist 1
LorcaserinPhase 1/2
No dated milestone in 2025 to 2030
Small molecule 1
MDR-001Phase 3
No dated milestone in 2025 to 2030